CIS-imidazolines as MDM2 inhibitors

Details for Australian Patent Application No. 2004253245 (hide)

Owner F. Hoffmann-La Roche AG

Inventors Liu, Emily Aijun; Vu, Binh Thanh; Fotouhi, Nader

Agent Davies Collison Cave

Pub. Number AU-B-2004253245

PCT Pub. Number WO2005/002575

Priority 60/479,563 17.06.03 US

Filing date 9 June 2004

Wipo publication date 13 January 2005

Acceptance publication date 11 February 2010

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

C07D 233/22 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings

C07D 401/06 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 403/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/002575 Priority application(s): WO2005/002575

11 February 2010 Application Accepted

  Published as AU-B-2004253245

10 June 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253246-Nutrition bar

2004253242-Formulations for the treatment of arhritis conditions